ClinicalTrials.gg
CompletedNCT04657003SURMOUNT-2Updated Apr 8, 2024Results posted

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

A Phase 3 interventional study of Tirzepatide and Placebo in Type 2 Diabetes, Overweight and Obesity, sponsored by Eli Lilly and Company. Completed at 75 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-08.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
938
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Enrollment
6th of 43
938 · median 160
Started
2021
the only one that year
Phase 3
17 of 43
1 open now
Registered
19th of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 6th largest by enrollment, is the only one that started in 2021, is one of 17 in phase 3, and was the 19th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).

03

Conditions studied

  • Type 2 Diabetes
  • Overweight
  • Obesity

Keywords

  • Metabolism and Nutrition Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Type 2 Diabetes (T2DM) with ≥7% to ≤10% at screening, on stable therapy for the last 3 months prior to screening. T2DM may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling) EXCEPT dipeptidyl peptidase 4 (DPP-4) inhibitors or glucagon like peptide-1 receptor agonists (GLP-1 RAs)
  • Have a of ≥27 kg/m²
  • Are overweight or have obesity
  • Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight
  • Are at least 18 years of age and age of majority per local laws and regulations

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except T2DM
  • Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values >270 mg/dL(on 2 nonconsecutive days) prior to Visit 3
  • Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment
  • Have self-reported change in body weight >5kg within 3 months prior to screening
  • Have had a history of chronic or acute pancreatitis
  • Change in body weight greater than 5 kg within 3 months prior to starting study
  • Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity
  • Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years
  • Any lifetime history of a suicide attempt
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
938 participants (actual)

Study arms

  • Experimental
    10 milligrams (mg) Tirzepatide

    10 mg Tirzepatide administered subcutaneously (SC) once weekly (QW)

    Drug: Tirzepatide

  • Experimental
    15 mg Tirzepatide

    15 mg Tirzepatide administered SC QW

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Placebo administered SC QW

    Other: Placebo

Interventions

  • Administered SC

    Also known as: LY3298176

  • OtherPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight

    Least Squares Mean (LSMean) calculated using Mixed Model Repeated Measures (MMRM) model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of Antihyperglycemic Medication (AHM) Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 72

  2. Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline

    Percentage of participants who achieve ≥5% body weight reduction from baseline

    Time frame: Week 72

Secondary outcomes

  1. Percentage of Participants Who Achieve ≥10% Body Weight Reduction From Baseline

    Percentage of participants who achieve ≥10% body weight reduction from baseline

    Time frame: Week 72

  2. Percentage of Participants Who Achieve ≥15% Body Weight Reduction From Baseline

    Percentage of participants who achieve ≥15% body weight reduction from baseline

    Time frame: Week 72

  3. Percentage of Participants Who Achieve ≥20% Body Weight Reduction From Baseline

    Percentage of participants who achieve ≥20% body weight reduction from baseline

    Time frame: Week 72

  4. Change From Baseline in Absolute Body Weight

    LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 72

  5. Change From Baseline in Body Mass Index (BMI)

    LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 72

  6. Change From Baseline in Hemoglobin A1c (HbA1c)

    LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 72

  7. Percentage of Participants Who Achieve HbA1c <7%

    Percentage of participants who achieve HbA1c \<7%

    Time frame: Week 72

  8. Percentage of Participants Who Achieve HbA1c ≤6.5%

    Percentage of participants who achieve HbA1c ≤6.5%

    Time frame: Week 72

  9. Percentage of Participants Who Achieve HbA1c <5.7%

    Percentage of participants who achieve HbA1c \<5.7%

    Time frame: Week 72

  10. Change From Baseline in Fasting Glucose

    LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 72

  11. Change From Baseline in Waist Circumference

    LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 72

  12. Percent Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

    Results are reported as model-based estimates and standard error (SE) from MMRM analysis using log transformation.

    Time frame: Baseline, Week 72

  13. Percent Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

    Results are reported as model-based estimates and SE from MMRM analysis using log transformation.

    Time frame: Baseline, Week 72

  14. Percent Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

    Results are reported as model-based estimates and SE from MMRM analysis using log transformation.

    Time frame: Baseline, Week 72

  15. Percent Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

    Results are reported as model-based estimates and SE from MMRM analysis using log transformation.

    Time frame: Baseline, Week 72

  16. Percent Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg)

    Results are reported as model-based estimates and SE from MMRM analysis using log transformation.

    Time frame: Baseline, Week 72

  17. Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

    Results are reported as model-based estimates and SE from MMRM analysis using log transformation.

    Time frame: Baseline, Week 72

  18. Percent Change From Baseline in Free Fatty Acids (Pooled Doses of 10 mg and 15 mg Tirzepatide)

    Results are reported as model-based estimates and SE from MMRM analysis using log transformation.

    Time frame: Baseline, Week 72

  19. Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide)

    LSMean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 72

  20. Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide)

    LSMean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 72

  21. Percent Change From Baseline in Fasting Insulin

    Results are reported as model-based estimates and SE from MMRM analysis using log transformation.

    Time frame: Baseline, Week 72

  22. Change From Baseline in Short Form 36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score

    The SF-36v2 acute, 1-week recall version is a 36-item, generic, patient-administered measure designed to assess the following 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" while the remaining domains assess functioning "in the past week." Each domain is scored individually and information from these 8 domains are further aggregated into 2 health-component summary scores: Physical-Component Summary and Mental-Component Summary. Items are answered on Likert scales of varying lengths (3-, 5-, or 6- point scales).The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.

    Time frame: Baseline, Week 72

  23. Change From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL Lite-CT) Physical Function Composite Score

    The IWQOL-Lite-CT is a 20-item, obesity-specific patient reported outcome (PRO) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life.

    Time frame: Baseline, Week 72

  24. Population Pharmacokinetics (PopPK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide

    Each participant was assigned via the Interactive Web Response System (IWRS) to one of the sampling PK time windows of 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours postdose. The steady state AUC was evaluated using Population PK modeling.

    Time frame: Week 8, 16, 36: 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours postdose

07

Results

Posted Apr 8, 2024

Participant flow

Participant flow — Overall Study
MilestonePlacebo10 Milligrams (mg) Tirzepatide15 mg Tirzepatide
Started315312311
Received at least one dose of study drug315312311
Completed281296282
Not completed341629
Withdrew: Adverse event515
Withdrew: Death020
Withdrew: Lost to follow-up8410
Withdrew: Other - as reported by investigator322
Withdrew: Pregnancy202
Withdrew: Withdrawal by subject16710

Outcome measures

PrimaryPercent Change From Baseline in Body Weight

Least Squares Mean (LSMean) calculated using Mixed Model Repeated Measures (MMRM) model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of Antihyperglycemic Medication (AHM) Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Weight
percent changePlacebo10 mg Tirzepatide15 mg Tirzepatide
Percent Change From Baseline in Body Weight-3.3 ± 0.49-13.4 ± 0.48-15.7 ± 0.49
Statistical analysis
  • Placebo vs 10 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Lsmean mean difference (net): -10.1 · 95% CI -11.5 to -8.8
  • Placebo vs 15 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Lsmean mean difference (net): -12.4 · 95% CI -13.7 to -11.0
PrimaryPercentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline

Percentage of participants who achieve ≥5% body weight reduction from baseline

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline
percentage of participantsPlacebo10 mg Tirzepatide15 mg Tirzepatide
Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline30.5581.5586.41
Statistical analysis
  • Placebo vs 10 mg Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 10.75 · 95% CI 7.30 to 15.84
  • Placebo vs 15 mg Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 15.28 · 95% CI 10.08 to 23.14
SecondaryPercentage of Participants Who Achieve ≥10% Body Weight Reduction From Baseline

Percentage of participants who achieve ≥10% body weight reduction from baseline

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve ≥10% Body Weight Reduction From Baseline
percentage of participantsPlacebo10 mg Tirzepatide15 mg Tirzepatide
Percentage of Participants Who Achieve ≥10% Body Weight Reduction From Baseline8.6863.4369.58
Statistical analysis
  • Placebo vs 10 mg Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 20.94 · 95% CI 13.06 to 33.58
  • Placebo vs 15 mg Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 27.50 · 95% CI 17.04 to 44.39
SecondaryPercentage of Participants Who Achieve ≥15% Body Weight Reduction From Baseline

Percentage of participants who achieve ≥15% body weight reduction from baseline

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve ≥15% Body Weight Reduction From Baseline
percentage of participantsPlacebo10 mg Tirzepatide15 mg Tirzepatide
Percentage of Participants Who Achieve ≥15% Body Weight Reduction From Baseline2.5741.4251.78
Statistical analysis
  • Placebo vs 10 mg Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 28.38 · 95% CI 13.81 to 58.31
  • Placebo vs 15 mg Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 43.60 · 95% CI 21.20 to 89.67
SecondaryPercentage of Participants Who Achieve ≥20% Body Weight Reduction From Baseline

Percentage of participants who achieve ≥20% body weight reduction from baseline

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve ≥20% Body Weight Reduction From Baseline
percentage of participantsPlacebo10 mg Tirzepatide15 mg Tirzepatide
Percentage of Participants Who Achieve ≥20% Body Weight Reduction From Baseline0.9622.9833.98
Statistical analysis
  • Placebo vs 10 mg Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 28.54 · 95% CI 9.73 to 83.73
  • Placebo vs 15 mg Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 49.68 · 95% CI 17.03 to 144.94
SecondaryChange From Baseline in Absolute Body Weight

LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline in Absolute Body Weight
kilograms (kg)Placebo10 mg Tirzepatide15 mg Tirzepatide
Change From Baseline in Absolute Body Weight-3.2 ± 0.51-13.5 ± 0.51-15.6 ± 0.51
Statistical analysis
  • Placebo vs 10 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Lsmean mean difference (net): -10.3 · 95% CI -11.7 to -8.8
  • Placebo vs 15 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Lsmean mean difference (net): -12.4 · 95% CI -13.8 to -11.0
SecondaryChange From Baseline in Body Mass Index (BMI)

LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · kilograms per meter squared (kg/m^2)
Change From Baseline in Body Mass Index (BMI)
kilograms per meter squared (kg/m^2)Placebo10 mg Tirzepatide15 mg Tirzepatide
Change From Baseline in Body Mass Index (BMI)-1.2 ± 0.19-4.9 ± 0.18-5.7 ± 0.19
Statistical analysis
  • Placebo vs 10 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Lsmean mean difference (net): -3.7 · 95% CI -4.2 to -3.2
  • Placebo vs 15 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Lsmean mean difference (net): -4.5 · 95% CI -5.0 to -4.0
SecondaryChange From Baseline in Hemoglobin A1c (HbA1c)

LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c)
percentage of HbA1cPlacebo10 mg Tirzepatide15 mg Tirzepatide
Change From Baseline in Hemoglobin A1c (HbA1c)-0.16 ± 0.067-2.14 ± 0.060-2.22 ± 0.060
Statistical analysis
  • Placebo vs 10 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Lsmean mean difference (net): -1.97 · 95% CI -2.15 to -1.80
  • Placebo vs 15 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Lsmean mean difference (net): -2.06 · 95% CI -2.24 to -1.88
SecondaryPercentage of Participants Who Achieve HbA1c <7%

Percentage of participants who achieve HbA1c \<7%

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve HbA1c <7%
percentage of participantsPlacebo10 mg Tirzepatide15 mg Tirzepatide
Percentage of Participants Who Achieve HbA1c <7%29.3190.0390.67
Statistical analysis
  • Placebo vs 10 mg Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 28.01 · 95% CI 17.21 to 45.59
  • Placebo vs 15 mg Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 34.19 · 95% CI 20.27 to 57.67
SecondaryPercentage of Participants Who Achieve HbA1c ≤6.5%

Percentage of participants who achieve HbA1c ≤6.5%

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve HbA1c ≤6.5%
percentage of participantsPlacebo10 mg Tirzepatide15 mg Tirzepatide
Percentage of Participants Who Achieve HbA1c ≤6.5%15.5284.0586.67
Statistical analysis
  • Placebo vs 10 mg Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 42.11 · 95% CI 25.61 to 69.26
  • Placebo vs 15 mg Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 58.67 · 95% CI 34.29 to 100.37
SecondaryPercentage of Participants Who Achieve HbA1c <5.7%

Percentage of participants who achieve HbA1c \<5.7%

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve HbA1c <5.7%
percentage of participantsPlacebo10 mg Tirzepatide15 mg Tirzepatide
Percentage of Participants Who Achieve HbA1c <5.7%2.7650.1755.33
Statistical analysis
  • Placebo vs 10 mg Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 42.55 · 95% CI 20.46 to 88.50
  • Placebo vs 15 mg Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 54.30 · 95% CI 26.00 to 113.38
SecondaryChange From Baseline in Fasting Glucose

LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Glucose
milligrams per deciliter (mg/dL)Placebo10 mg Tirzepatide15 mg Tirzepatide
Change From Baseline in Fasting Glucose-2.42 ± 2.281-49.20 ± 1.940-51.67 ± 1.970
Statistical analysis
  • Placebo vs 10 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Lsmean mean difference (net): -46.79 · 95% CI -52.67 to -40.91
  • Placebo vs 15 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Lsmean mean difference (net): -49.25 · 95% CI -55.18 to -43.33
SecondaryChange From Baseline in Waist Circumference

LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · centimeters (cm)
Change From Baseline in Waist Circumference
centimeters (cm)Placebo10 mg Tirzepatide15 mg Tirzepatide
Change From Baseline in Waist Circumference-3.4 ± 0.51-11.2 ± 0.50-13.8 ± 0.51
Statistical analysis
  • Placebo vs 10 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Lsmean mean difference (net): -7.8 · 95% CI -9.2 to -6.4
  • Placebo vs 15 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Lsmean mean difference (net): -10.4 · 95% CI -11.8 to -8.9
SecondaryPercent Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Results are reported as model-based estimates and standard error (SE) from MMRM analysis using log transformation.

Time frame:
Baseline, Week 72
Reported as:
Mean · percent change
Percent Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
percent changePlaceboPooled 10 mg and 15 mg Tirzepatide
Percent Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)2.13 ± 1.135-2.58 ± 0.755
Statistical analysis
  • Placebo vs Pooled 10 mg and 15 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Estimate difference: -4.61 · 95% CI -7.11 to -2.03
SecondaryPercent Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Results are reported as model-based estimates and SE from MMRM analysis using log transformation.

Time frame:
Baseline, Week 72
Reported as:
Mean · percent change
Percent Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
percent changePlaceboPooled 10 mg and 15 mg Tirzepatide
Percent Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)6.29 ± 1.8742.72 ± 1.264
Statistical analysis
  • Placebo vs Pooled 10 mg and 15 mg Tirzepatide · Mixed Models Analysis · p = 0.112 · Estimate difference: -3.36 · 95% CI -7.36 to 0.81
SecondaryPercent Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Results are reported as model-based estimates and SE from MMRM analysis using log transformation.

Time frame:
Baseline, Week 72
Reported as:
Mean · percent change
Percent Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
percent changePlaceboPooled 10 mg and 15 mg Tirzepatide
Percent Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)1.10 ± 1.0488.19 ± 0.782
Statistical analysis
  • Placebo vs Pooled 10 mg and 15 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Estimate difference: 7.02 · 95% CI 4.40 to 9.71
SecondaryPercent Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Results are reported as model-based estimates and SE from MMRM analysis using log transformation.

Time frame:
Baseline, Week 72
Reported as:
Mean · percent change
Percent Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
percent changePlaceboPooled 10 mg and 15 mg Tirzepatide
Percent Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)-6.0 ± 2.18-27.9 ± 1.16
Statistical analysis
  • Placebo vs Pooled 10 mg and 15 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Estimate difference: -23.3 · 95% CI -27.5 to -18.9
SecondaryPercent Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Results are reported as model-based estimates and SE from MMRM analysis using log transformation.

Time frame:
Baseline, Week 72
Reported as:
Mean · percent change
Percent Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg)
percent changePlaceboPooled 10 mg and 15 mg Tirzepatide
Percent Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg)-5.8 ± 2.32-28.6 ± 1.22
Statistical analysis
  • Placebo vs Pooled 10 mg and 15 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Estimate difference: -24.2 · 95% CI -28.6 to -19.6
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Results are reported as model-based estimates and SE from MMRM analysis using log transformation.

Time frame:
Baseline, Week 72
Reported as:
Mean · percent change
Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
percent changePlaceboPooled Doses of 10 mg and 15 mg Tirzepatide
Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)2.30 ± 1.573-6.64 ± 1.001
Statistical analysis
  • Placebo vs Pooled Doses of 10 mg and 15 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Estimate difference: -8.74 · 95% CI -12.04 to -5.32
SecondaryPercent Change From Baseline in Free Fatty Acids (Pooled Doses of 10 mg and 15 mg Tirzepatide)

Results are reported as model-based estimates and SE from MMRM analysis using log transformation.

Time frame:
Baseline, Week 72
Reported as:
Mean · percent change
Percent Change From Baseline in Free Fatty Acids (Pooled Doses of 10 mg and 15 mg Tirzepatide)
percent changePlaceboPooled 10 mg and 15 mg Tirzepatide
Percent Change From Baseline in Free Fatty Acids (Pooled Doses of 10 mg and 15 mg Tirzepatide)0.03 ± 2.838-23.58 ± 1.502
Statistical analysis
  • Placebo vs Pooled 10 mg and 15 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Estimate difference: -23.61 · 95% CI -28.62 to -18.24
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide)

LSMean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide)
millimeters of mercury (mmHg)PlaceboPooled 10 mg and 15 mg Tirzepatide
Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide)-1.0 ± 0.74-7.2 ± 0.52
Statistical analysis
  • Placebo vs Pooled 10 mg and 15 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Lsmean mean difference (net): -6.2 · 95% CI -8.0 to -4.4
SecondaryChange From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide)

LSMean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide)
millimeters of mercury (mmHg)PlaceboPooled Doses of 10 mg and 15 mg Tirzepatide
Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide)-0.2 ± 0.45-2.6 ± 0.31
Statistical analysis
  • Placebo vs Pooled Doses of 10 mg and 15 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Lsmean mean difference (net): -2.4 · 95% CI -3.5 to -1.3
SecondaryPercent Change From Baseline in Fasting Insulin

Results are reported as model-based estimates and SE from MMRM analysis using log transformation.

Time frame:
Baseline, Week 72
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Insulin
percent changePlacebo10 mg Tirzepatide15 mg Tirzepatide
Percent Change From Baseline in Fasting Insulin-14.5 ± 3.39-29.6 ± 2.28-40.3 ± 1.99
Statistical analysis
  • Placebo vs 10 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Estimate difference: -17.6 · 95% CI -25.5 to -8.9
  • Placebo vs 15 mg Tirzepatide · Mixed Models Analysis · p = <0.001 · Estimate difference: -30.2 · 95% CI -37.0 to -22.7
SecondaryChange From Baseline in Short Form 36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score

The SF-36v2 acute, 1-week recall version is a 36-item, generic, patient-administered measure designed to assess the following 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" while the remaining domains assess functioning "in the past week." Each domain is scored individually and information from these 8 domains are further aggregated into 2 health-component summary scores: Physical-Component Summary and Mental-Component Summary. Items are answered on Likert scales of varying lengths (3-, 5-, or 6- point scales).The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · score on a scale
Change From Baseline in Short Form 36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score
score on a scalePlacebo10 mg Tirzepatide15 mg Tirzepatide
Change From Baseline in Short Form 36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score1.6 ± 0.403.4 ± 0.393.8 ± 0.40
Statistical analysis
  • Placebo vs 10 mg Tirzepatide · ANCOVA · p = 0.001 · Lsmean mean difference (net): 1.8 · 95% CI 0.7 to 2.9
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = <0.001 · Lsmean mean difference (net): 2.3 · 95% CI 1.1 to 3.4
SecondaryChange From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL Lite-CT) Physical Function Composite Score

The IWQOL-Lite-CT is a 20-item, obesity-specific patient reported outcome (PRO) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · score on a scale
Change From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL Lite-CT) Physical Function Composite Score
score on a scalePlacebo10 mg Tirzepatide15 mg Tirzepatide
Change From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL Lite-CT) Physical Function Composite Score7.4 ± 1.0314.3 ± 1.0015.2 ± 1.03
Statistical analysis
  • Placebo vs 10 mg Tirzepatide · ANCOVA · p = <0.001 · Lsmean difference (net): 6.9 · 95% CI 4.1 to 9.7
  • Placebo vs 15 mg Tirzepatide · ANCOVA · p = <0.001 · Lsmean difference (net): 7.8 · 95% CI 5.0 to 10.7
SecondaryPopulation Pharmacokinetics (PopPK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide

Each participant was assigned via the Interactive Web Response System (IWRS) to one of the sampling PK time windows of 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours postdose. The steady state AUC was evaluated using Population PK modeling.

Time frame:
Week 8, 16, 36: 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours postdose
Reported as:
Geometric mean · nanograms*hour per milliliter (ng*h/mL)
Population Pharmacokinetics (PopPK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide
nanograms*hour per milliliter (ng*h/mL)10 mg Tirzepatide15 mg Tirzepatide
Population Pharmacokinetics (PopPK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide153000 ± 19.5234000 ± 19.2

Adverse events

Collected over Baseline through Week 76. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/315 (0%)23/315 (7.3%)158/315 (50.2%)
10 mg Tirzepatide2/312 (0.6%)18/312 (5.8%)169/312 (54.2%)
15 mg Tirzepatide0/311 (0%)27/311 (8.7%)159/311 (51.1%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventPlacebo10 mg Tirzepatide15 mg Tirzepatide
Acute kidney injuryRenal and urinary disorders1/3153/3120/311
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1560/1541/152
Pancreatitis acuteGastrointestinal disorders0/3150/3122/311
Cholecystitis acuteHepatobiliary disorders2/3151/3122/311
CholelithiasisHepatobiliary disorders1/3150/3122/311
CellulitisInfections and infestations0/3150/3122/311
Ischaemic strokeNervous system disorders0/3150/3122/311
GastroenteritisInfections and infestations0/3152/3120/311
Covid-19 pneumoniaInfections and infestations2/3150/3121/311
AdenomyosisReproductive system and breast disorders0/1591/1580/159
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlacebo10 mg Tirzepatide15 mg Tirzepatide
NauseaGastrointestinal disorders20/31563/31268/311
DiarrhoeaGastrointestinal disorders28/31562/31266/311
Covid-19Infections and infestations53/31552/31233/311
HyperglycaemiaMetabolism and nutrition disorders45/3156/3124/311
VomitingGastrointestinal disorders10/31534/31240/311
Decreased appetiteMetabolism and nutrition disorders7/31530/31231/311
ConstipationGastrointestinal disorders13/31525/31228/311
Abdominal painGastrointestinal disorders7/31512/31223/311
DyspepsiaGastrointestinal disorders10/31523/31222/311
Upper respiratory tract infectionInfections and infestations21/31510/31212/311

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Placebo10 mg Tirzepatide15 mg TirzepatideTotal
Mean54.7 ± 10.554.3 ± 10.753.6 ± 10.654.2 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Placebo10 mg Tirzepatide15 mg TirzepatideTotal
Female159158159476
Male156154152462
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo10 mg Tirzepatide15 mg TirzepatideTotal
Hispanic or Latino188184189561
Not Hispanic or Latino122124112358
Unknown or Not Reported541019
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo10 mg Tirzepatide15 mg TirzepatideTotal
American Indian or Alaska Native0000
Asian394442125
Native Hawaiian or Other Pacific Islander1113
Black or African American22332277
White248228234710
More than one race561223
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Placebo10 mg Tirzepatide15 mg TirzepatideTotal
Argentina116115115346
Brazil30293089
India98926
Japan21242267
Russia17131343
Taiwan89825
United States114114114342
Weight
Weight(kilograms (kg))Placebo10 mg Tirzepatide15 mg TirzepatideTotal
Mean101.65 ± 22.26100.86 ± 20.9399.60 ± 20.05100.71 ± 21.10
08

Study locations

75 sites
  • University of Alabama - Department of Nutrition Sciences
    Birmingham, Alabama 35294, United States
  • KLR Business Group, Inc. dba Arkansas Clinical Research
    Little Rock, Arkansas 72205, United States
  • Velocity Clinical Research, Huntington Park
    Huntington Park, California 90255, United States
  • Velocity Clinical Research, Westlake
    Los Angeles, California 90057, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • University Clinical Investigators, Inc.
    Tustin, California 92780, United States
  • ALL Medical Research, LLC
    Cooper City, Florida 33024, United States
  • Northeast Research Institute (NERI)
    Fleming Island, Florida 32003, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • West Orange Endocrinology
    Ocoee, Florida 34761, United States
  • Metabolic Research Institute, Inc.
    West Palm Beach, Florida 33401, United States
  • Emory University School of Medicine- Grady Campus
    Atlanta, Georgia 30303, United States
  • East Coast Institute for Research, LLC
    Macon, Georgia 31210, United States
  • Pacific Diabetes & Endocrine Center
    Honolulu, Hawaii 96813, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • Rocky Mountain Clinical Research
    Idaho Falls, Idaho 83404, United States
  • American Health Network of Indiana, LLC - Greenfield
    Greenfield, Indiana 46140, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • Cotton O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • Maryland Cardiovascular Specialists
    Baltimore, Maryland 21229, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • NECCR PrimaCare Research
    Fall River, Massachusetts 02721, United States
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
    Troy, Michigan 48098, United States
  • Logan Health Research
    Kalispell, Montana 59901, United States
  • Premier Research
    Trenton, New Jersey 08611, United States
  • University of North Carolina Medical Center
    Chapel Hill, North Carolina 27514, United States
  • PharmQuest
    Greensboro, North Carolina 27408, United States
  • Wake Forest University Baptist Medical Center (WFUBMC)
    Winston-Salem, North Carolina 27157, United States
  • Velocity Clinical Research, Cleveland
    Cleveland, Ohio 44122, United States
  • Aventiv Research
    Dublin, Ohio 43016, United States
  • The Corvallis Clinic, P.C.
    Corvallis, Oregon 97330, United States
  • Preferred Primary Care Physicians
    Uniontown, Pennsylvania 15401, United States
  • Center for Neurosciences
    Warwick, Rhode Island 02886, United States
  • Tribe Clinical Research, LLC
    Greenville, South Carolina 29607, United States
  • Texas Diabetes & Endocrinology, P.A.
    Austin, Texas 78749, United States
  • Dallas Diabetes Research Center
    Dallas, Texas 75230, United States
  • Diabetes and Thyroid Center of Fort Worth
    Fort Worth, Texas 76132, United States
  • Juno Research
    Houston, Texas 77040, United States
  • Endocrine Ips, Pllc
    Houston, Texas 77079, United States
  • Health Research of Hampton Roads, Inc.
    Newport News, Virginia 23606, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
  • Clinical Investigation Specialists
    Kenosha, Wisconsin 53144, United States
  • Consultorio de Investigación Clínica EMO SRL
    Ciudad Autonoma de Buenos Aire, Buenos Aires C1405BUB, Argentina
  • Centro de Investigaciones Metabólicas (CINME)
    Ciudad Autónoma de Buenos Aire, Buenos Aires 1056, Argentina
  • Instituto de Investigaciones Clínicas Mar del Plata
    Mar del Plata, Buenos Aires 7600, Argentina
  • Go Centro Medico San Nicolás
    San Nicolas, Buenos Aires 2900, Argentina
  • Centro Médico Viamonte
    Buenos Aires, Ciudad Autónoma De Buenos Aire C1120AAC, Argentina
  • CIPREC
    Caba, Ciudad Autónoma De Buenos Aire C1061AAS, Argentina
  • Centro de Investigaciones Médicas Tucuman
    SAN M. DE Tucuman, Tucumán T4000AXL, Argentina
  • Sanatorio Norte
    Santiago del Estero, 4200, Argentina
  • Private Practice - Dr.Miguel N. Hissa
    Fortaleza, Ceará 60430-350, Brazil
  • Loema Instituto de Pesquisa Clinica
    Campinas, São Paulo 13010-001, Brazil
  • Instituto de Pesquisa clinica de Campinas
    Campinas, São Paulo 13060-080, Brazil
  • CECIP - Centro de Estudos do Interior Paulista
    Jaú, São Paulo 17201130, Brazil
  • CPCLIN
    Sao Paulo, São Paulo 01228-200, Brazil
  • CEPIC - Centro Paulista de Investigação Clínica
    São Paulo, 04266-010, Brazil
  • Life Care Hospital and Research Centre
    Bangalore, Karnataka 560092, India
  • ILS Hospitals
    Kolkata, West Bengal 700064, India
  • Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic
    Yamato-shi, Kanagawa 242-0004, Japan
  • Medical Corporation Heishinkai OCROM Clinic
    Suita-shi, Osaka 565-0853, Japan
  • Medical Corporation Sato Medical clinic
    Ootaku, Tokyo 143-0015, Japan
  • AMC Nishiumeda Clinic
    Osaka, 530-0001, Japan
  • Centro de Endocrinologia y Nutricion
    Caguas, 00725, Puerto Rico
  • Latin Clinical Trial Center
    San Juan, 00909, Puerto Rico
  • GCM Medical Group, PSC - Hato Rey Site
    San Juan, 917, Puerto Rico
  • Endocrinology Research Center of Rosmedtechnologies
    Moscow, Moskva 117036, Russian Federation
  • Russian Medical Academy of Postgraduate Education
    Moscow, Moskva 125284, Russian Federation
  • Saint-Petersburg City Hospital of Saint Elizabeth
    Saint Petersburg, Sankt-Pete 195257, Russian Federation
  • Smolensk State Medical University
    Smolensk, 214019, Russian Federation
  • Changhua Christian Hospital
    Changhua County, Changhua 50006, Taiwan
  • Chi Mei Medical Center
    Tainan City, Tainan 71004, Taiwan
  • Chung Shan Medical University Hospital
    Taichung, 402, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 407, Taiwan
  • National Cheng-Kung Uni. Hosp.
    Tainan, 704, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Time Frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Mar 2023, 23 months.

Results were first posted in Apr 2024, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 23 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Dec 7, 2020
StartActual
Mar 29, 2021
Primary completionActual
Mar 16, 2023
CompletionActual
Apr 10, 2023
Results first posted
Apr 8, 2024
Last update
Apr 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04657003
Responsible party
Sponsor
First posted
Dec 7, 2020
Start date
Mar 29, 2021
Primary completion
Mar 16, 2023
Completion
Apr 10, 2023
Results posted
Apr 8, 2024
Last update
Apr 8, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion